Niacin Forms: Nicotinic Acid, Nicotinamide, and Inositol Hexanicotinate — Three Different Drugs Sold as One Vitamin

The retail niacin shelf runs a bait-and-switch that most buyers never catch, because the switch happens inside the parenthetical descriptor on the Supplement Facts panel and the front-of-label "Niacin 500 mg" claim covers for all three variants without disclosing which one is in the capsule. The three molecules the category ships — nicotinic acid, nicotinamide (also called niacinamide), and inositol hexanicotinate (also called inositol hexaniacinate, hexanicotinate, or "no-flush niacin") — share the same regulatory umbrella as "vitamin B3" and the same label name on the front panel. They are not interchangeable. They have different pharmacokinetics, different clinical indications, different studied dose brackets, different adverse-event profiles, and exactly one of the three has the trial literature behind the cholesterol-lowering, HDL-raising, lipoprotein(a)-lowering effect that drives most of the demand for the ingredient in the first place.

The Three Molecules and the Shared "Vitamin B3" Umbrella

Nicotinic acid (niacin). The free carboxylic-acid form. Converted in vivo to nicotinamide and then to the NAD/NADP coenzyme pool for every one-carbon-metabolism and redox-biology reaction the cell runs. The form the 1950s Altschul and Hoffer work used to establish the lipid-modifying indication, the form the Coronary Drug Project (1975), the HATS trial (2001), the AIM-HIGH trial (2011), and the HPS2-THRIVE trial (2014) tested, the form of prescription niacin (Niaspan, extended-release niacin), and the only form that produces the HMG-CoA-reductase-independent lipid-modifying effect at supraphysiologic doses. Produces the characteristic cutaneous "niacin flush" — prostaglandin D2-mediated vasodilation of skin capillaries 15 to 30 minutes after dosing, lasting 30 to 90 minutes, warm-face-and-chest-and-arm sensation with visible erythema. The flush is pharmacologically coupled to the lipid-modifying effect: both run through the HM74A (GPR109A) receptor on adipocytes and skin Langerhans cells, and the receptor engagement that produces the lipid effect also produces the flush.

Nicotinamide (niacinamide). The amide form. Also enters the NAD/NADP pool and functions as a vitamin equivalent for the one-carbon and redox roles. Does NOT engage the GPR109A receptor at any physiologically relevant dose. Does NOT produce the flush, does NOT lower LDL, does NOT lower triglycerides, does NOT lower lipoprotein(a), does NOT raise HDL. The form that fills most generic multivitamins and most "no-flush niacin" marketing (though "no-flush" more often refers to inositol hexanicotinate — see below). Clinical indication base is distinct from the lipid literature: topical and oral nicotinamide at 500 mg twice daily reduced non-melanoma skin cancer incidence by 23 percent in the ONTRAC trial (2015); nicotinamide is a candidate neuroprotective agent in early Parkinson's and Alzheimer's work; nicotinamide supports NAD-pool restoration in the general health literature at lower doses than the dedicated NR/NMN precursor products target.

Inositol hexanicotinate (IHN). A molecule of myo-inositol with six nicotinic-acid groups esterified onto the hydroxyl positions. Marketed as "no-flush niacin" because the ester bond prevents the molecule from engaging GPR109A at the normal dose and schedule. In vivo hydrolysis of the ester bonds in humans is slow and incomplete — the controlled PK and clinical trial work (Keenan 1991 among others) measures free nicotinic acid release at approximately 5 to 10 percent of the administered IHN dose across a 24-hour window, which translates a 1000-mg IHN dose into roughly 50 to 100 mg of circulating nicotinic acid equivalent spread over the day. The lipid-modifying literature on IHN is thin, inconsistent, and generally negative. The 2003 Benjo meta-analysis and subsequent reviews land IHN at non-superior-to-placebo for the lipid markers that nicotinic acid moves cleanly in the Coronary Drug Project and HATS data. The ingredient is on the shelf because it is the only one of the three that captures the "I take niacin for my cholesterol without the flush" buyer, and the regulatory framework lets the "niacin" front-label claim stand regardless of the clinical indication base.

The Studied Dose Brackets by Indication and Form

Nicotinic acid for lipid modification. The trial-anchored lipid-modifying dose is 1500 to 3000 mg per day of nicotinic acid (not nicotinamide, not IHN), in a titrated schedule starting at 500 mg per day and advancing by 500-mg increments every 1 to 2 weeks against flush tolerance and liver-enzyme monitoring. The Coronary Drug Project used 3000 mg per day. The HATS trial used an initial 500 mg titrating to 1000 mg twice daily (2000 mg total). Prescription extended-release Niaspan is dosed 1000 to 2000 mg per day. The retail nicotinic-acid product at 500 mg per capsule intended for lipid modification is a titration starting point, not the destination dose. The retail nicotinic-acid product at 100 mg per capsule is well below any clinically meaningful lipid-modifying dose.

Nicotinic acid as a general B3 source. The IOM-RDA for niacin equivalents is 14 to 16 mg per day for adults. The tolerable upper intake level (UL) for added nicotinic acid is 35 mg per day, anchored against the flush threshold rather than against toxicity. A multivitamin that lists "niacin 20 mg (as nicotinic acid)" is operating in the vitamin-replacement range, not the lipid-modifying range. The product at this dose produces no lipid effect and no flush.

Nicotinamide for the dermatology and skin-cancer indication. The ONTRAC-protocol dose is 500 mg twice daily (1000 mg total) for 12 months in a high-risk non-melanoma-skin-cancer secondary prevention population. The topical dermatology dose for sebum regulation and anti-inflammatory effect runs 2 to 5 percent nicotinamide in a cream or serum vehicle; the oral dose for the same indication typically runs 500 to 1500 mg per day in the acne and rosacea literature.

Nicotinamide for NAD-pool support in the general health context. The dose brackets overlap with the dedicated NR and NMN precursor literature (300 to 1000 mg per day) but the comparative-efficacy question (nicotinamide at 500 mg vs NR at 500 mg vs NMN at 500 mg for NAD-pool elevation and the downstream biomarker outcomes) is unsettled across the published head-to-head work. The nicotinamide-at-500-mg buyer who assumes equivalence to the branded NR or NMN product at the same dose is extrapolating past the direct comparative evidence.

Inositol hexanicotinate for lipid modification. The commonly cited dose is 500 to 2000 mg per day as "no-flush niacin." The problem with the dose recommendation is that the controlled lipid-outcome trial base is thin and the systematic reviews land the molecule at approximately placebo-equivalent for the lipid markers. The IHN dose that WOULD produce a nicotinic-acid-equivalent lipid effect (if the ester hydrolysis ran at 100 percent) is roughly 1.3 to 2 times the target nicotinic-acid dose — but the hydrolysis fraction is 5 to 10 percent, not 100 percent, so even the 2000-mg IHN dose does not deliver the nicotinic-acid exposure needed for the lipid effect. The product sells on the clinical-sounding name of the parent nutrient against the pharmacology that will not produce the clinical outcome the label implies.

Niacinamide and the proprietary-blend B-complex trap. A B-complex or stress-formula blend disclosing "Vitamin B3 25 mg" without the parenthetical descriptor is almost always nicotinamide (because nicotinamide at 25 mg does not flush and does not require a cautionary flush-warning statement on the label; a nicotinic-acid product at the same dose, if it hit the flush-sensitive subset of buyers at or above the 35 mg UL in combination with their dietary B3 intake, would attract complaint traffic the manufacturer avoids). The ingredient listed as "Vitamin B3" or "Niacin" in a proprietary blend without disclosure is a nutrient-of-record addition to clear the micronutrient panel, not a lipid-modifying dose.

The Flush: Mechanism, Attenuation, and the Marketing Trap

The nicotinic-acid flush is a prostaglandin D2 (PGD2) release from skin Langerhans cells and macrophages, mediated by the GPR109A (HM74A) receptor that nicotinic acid activates and that nicotinamide and IHN do not activate at the normal dose. The PGD2 binds the DP1 receptor on cutaneous vasculature and produces the vasodilation. The onset is 15 to 30 minutes after an oral dose, the peak is 30 to 60 minutes, and the duration is 30 to 90 minutes. The sensation is a warm, prickly, flushed face-and-chest-and-arm effect with visible erythema and sometimes mild itching. The flush is not dangerous at the dose and schedule the lipid-titration protocol uses, is not an allergic reaction, and attenuates with repeated dosing — the flush at week 1 of a titration is substantially worse than the flush at week 4 at the same dose because the DP1 receptor downregulates against repeated PGD2 exposure.

Clinical attenuation protocols for the lipid-titration patient include aspirin 325 mg 30 to 60 minutes pre-dose (blocks the cyclooxygenase step that produces the PGD2), dosing with food (slows absorption and reduces the peak), slow titration up the dose ladder, and the extended-release Niaspan formulation (which spreads the absorption curve to blunt the peak). The flush, counterintuitively, is a biomarker that the drug is working: the GPR109A engagement that produces the flush is the same engagement that produces the adipocyte lipolysis suppression and the downstream lipid-modifying effect. The "no-flush niacin" marketing claim is implicitly a "no-mechanism niacin" claim.

The Lipid Trial Base and the Downgrade Trajectory

The nicotinic-acid lipid literature is one of the oldest in the cardiovascular pharmacology canon. The Altschul 1955 observation that nicotinic acid at gram doses lowered serum cholesterol in humans opened a 50-year arc of trial work. The Coronary Drug Project (1975) showed a 27-percent reduction in nonfatal MI and a 15-year follow-up mortality benefit with 3000 mg per day of immediate-release nicotinic acid in a secondary-prevention population. The HATS trial (2001) showed angiographic coronary stenosis reversal with the combination of nicotinic acid plus simvastatin against placebo. The HDL-raising, LDL-lowering, triglyceride-lowering, and lipoprotein(a)-lowering effects of nicotinic acid were established across these trials and the ingredient held a prescription-grade indication for cardiovascular risk reduction into the 2010s.

The downgrade trajectory came from two statin-era trials. AIM-HIGH (2011) randomized a statin-treated secondary-prevention population to add extended-release niacin against placebo and showed no cardiovascular-event benefit from the added niacin on top of statin-driven LDL control. HPS2-THRIVE (2014) replicated the no-event-benefit result in a larger population and surfaced a higher adverse-event rate (infection, bleeding, worsened glycemic control) on the niacin arm. The current clinical cardiology posture is that niacin's lipid-marker effect is real and remains documented in the published literature, but adding niacin to a statin-treated patient does not add measurable event-level cardiovascular benefit and does add measurable risk. The niacin monotherapy indication for the statin-intolerant or statin-ineligible patient remains defensible in careful hands under physician supervision.

The retail-shelf implications for the lipid-interested buyer are two. First, nicotinic-acid monotherapy for lipid modification is a physician-supervised intervention, not a self-directed one, because the dose range that produces the clinical effect sits at or above the hepatotoxicity-monitoring threshold and the schedule requires baseline and follow-up ALT/AST and glucose monitoring. Second, if the buyer is purchasing niacin on the shelf expecting a cholesterol-lowering effect, the product must disclose nicotinic acid in the parenthetical descriptor at a dose titrating toward the 1500-to-3000-mg daily range — the 500-mg nicotinamide capsule or the 500-mg IHN capsule will not produce the effect the marketing implies, regardless of how long the buyer takes it.

The Multi-Ingredient Blend Problem

"Cholesterol support" or "cardiovascular health" formulas commonly list Vitamin B3 at 50 to 500 mg per serving alongside red yeast rice, bergamot, policosanol, plant sterols, or berberine. The B3 ingredient in these formulas is almost always nicotinamide — because the proprietary-blend format pre-empts the per-ingredient flush warning that a nicotinic-acid dose at or above the UL would require. The ingredient on the label is doing the shelf-tag work of "cholesterol support formula contains B3," not the pharmacology work the lipid-modifying trial literature anchored. The clean multi-ingredient cardiovascular formula is one that discloses the B3 form explicitly in the parenthetical descriptor and either declares nicotinic acid at a clinically meaningful dose (uncommon on the shelf, because the flush and liver-enzyme monitoring push manufacturers toward the amide form) or omits a lipid-modifying claim from the marketing copy and positions the B3 ingredient as a vitamin-replacement dose only.

Energy and "metabolism support" blends commonly list Vitamin B3 at 15 to 50 mg paired with the rest of the B-complex. The ingredient at this dose is a vitamin-replacement addition, is almost always nicotinamide, produces no lipid effect, and is clinically indistinguishable from the B-complex dose in a general multivitamin. The product is not objectionable at this dose, but the "niacin boosts metabolism" marketing copy is extrapolating past what the ingredient-and-dose combination will deliver.

NAD-precursor and anti-aging stacks increasingly list nicotinamide at 300 to 1000 mg per day as a lower-cost alternative to NR or NMN. The ingredient at this dose does raise the NAD pool measurably and is not pharmacologically inert, but the comparative-efficacy question against the branded NR and NMN products at matched dose and schedule is unsettled, the end-point outcome literature is thin for all three precursors, and the buyer choosing nicotinamide over NR on cost grounds should know they are inside the active-trial-base window rather than against a well-settled head-to-head conclusion.

The Hepatotoxicity Signal — Extended-Release Niacin Specifically

The clinical hepatotoxicity signal in the niacin literature is concentrated in extended-release nicotinic-acid preparations at doses above 1500 mg per day. The mechanism is hepatocyte stress from the sustained nicotinic-acid exposure that the extended-release formulation produces (as opposed to the shorter peak-and-trough curve of the immediate-release form). ALT/AST monitoring at baseline, 6 weeks, and 12 weeks of a lipid-titration schedule is standard, and the signal typically appears as a 2-to-3-fold ALT elevation that reverses on dose reduction or discontinuation. Immediate-release nicotinic acid at the same daily dose carries a lower hepatotoxicity signal in the published comparative work but is harder to tolerate on the flush axis.

The over-the-counter extended-release nicotinic-acid product sold as "sustained-release niacin" or "SR niacin" without physician supervision is the formulation that generated most of the published OTC-use case reports of acute hepatotoxicity. The retail buyer who stacks a 500-to-1000-mg SR nicotinic-acid product daily on their own, without the baseline and follow-up liver-enzyme monitoring, is operating against the exact adverse-event profile the physician-supervised titration protocol was built to avoid.

Nicotinamide at supraphysiologic doses (above 3000 mg per day) carries its own hepatotoxicity signal in the published long-term work, but the signal is weaker and the daily doses commonly sold on the shelf (500 to 1000 mg) are generally well-tolerated across the clinical trial record.

Inositol hexanicotinate carries essentially no published hepatotoxicity signal, because the free nicotinic-acid exposure from the ester hydrolysis is low enough that the hepatocyte stress mechanism does not engage. The absence of the adverse-event signal is the same absence of the pharmacologic signal — the ester is not delivering the nicotinic-acid exposure needed to produce either the therapeutic effect or the dose-dependent adverse effect.

The Four-Question 20-Second Supplement Facts Read

1. What is the parenthetical descriptor under the Niacin or Vitamin B3 line? "(as nicotinic acid)" is the lipid-modifying form; "(as niacinamide)" or "(as nicotinamide)" is the NAD-and-skin form that does not move lipids; "(as inositol hexanicotinate)" or "(as inositol hexaniacinate)" is the ester form that does not deliver meaningful circulating nicotinic acid at the labeled dose. If the parenthetical is missing, assume nicotinamide.

2. Does the per-serving dose match a trial-anchored indication for the declared form? For nicotinic acid lipid modification: 1500 to 3000 mg per day titrated. For nicotinamide skin-cancer secondary prevention: 500 mg twice daily. For nicotinamide NAD-pool support: 300 to 1000 mg per day. For general B3 vitamin-replacement: 15 to 50 mg per day. Doses outside these brackets do not have a defensible indication the published literature supports.

3. Is the lipid-modifying marketing on the front of the label matched by the form on the back of the label? "Cholesterol support" or "HDL booster" or "lipoprotein support" with a nicotinamide or IHN form on the Supplement Facts panel is a mismatch and the product will not deliver the implied effect. "No-flush niacin" is the retail-shelf phrase for "the mechanism that produces the lipid effect is also the mechanism that produces the flush, and this product avoids both."

4. Is the product standalone or inside a proprietary blend? A proprietary blend disclosing Vitamin B3 at an undisclosed per-ingredient dose is a nutrient-of-record addition in nearly every case. The lipid-interested buyer buys the standalone product with the form and dose disclosed on the panel, not the multi-ingredient formula with the B3 ingredient hidden inside the blend.